Loading resource…

Daehoon Kim, M.D.
The study enrolled 1,803 participants with a CHA₂DS₂‑VASc score of 1 (men) or 2 (women) and randomly assigned them to DOAC therapy or no anticoagulation. The primary composite endpoint included stroke, systemic embolism, major bleeding, or cardiovascular death over 24 months. Results showed a lower incidence of the composite outcome in the DOAC group, while serious adverse events were comparable between groups. Baseline characteristics, safety data, and detailed adverse‑event tables are provided. The trial addresses the evidence gap highlighted by current U.S. and European guidelines for this risk category.
No account needed